Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
68.37 USD | -0.19% | +1.57% | +9.40% |
Mar. 21 | Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing | MT |
Mar. 12 | Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.43B |
---|---|---|---|---|---|
Net income 2024 * | -464M | Net income 2025 * | -509M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-16.1
x | P/E ratio 2025 * |
-15.2
x | Employees | 254 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.77% |
Latest transcript on Vaxcyte, Inc.
1 day | +1.60% | ||
1 week | -0.91% | ||
Current month | -7.21% | ||
1 month | -15.48% | ||
3 months | +8.03% | ||
6 months | +33.24% | ||
Current year | +9.08% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Director of Finance/CFO | 55 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Director/Board Member | 58 | 21-09-15 | |
Michael Kamarck
BRD | Director/Board Member | 73 | 21-10-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.27% | 0 M€ | 0.00% | - | |
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 68.65 | +0.22% | 244 659 |
24-03-27 | 68.5 | +1.60% | 523,354 |
24-03-26 | 67.42 | +1.58% | 548,809 |
24-03-25 | 66.37 | -1.28% | 379,932 |
24-03-22 | 67.23 | -0.61% | 366,085 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.08% | 7.43B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.45% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |